The East-West Bio Brief

Akeso drug enters priority review; ziltivekimab trials miss endpoints; Lifetech investment structure detailed

12 min Listen to the original Episode page
AkesoivonescimabziltivekimabHORIZON trialZEUS trialLifetech ScientificAllistBiotech Regulatory

Summary

Ning and Basil Lui discuss Akeso's ivonescimab entering China's priority review pathway, clarifying this is a regulatory step distinct from marketing approval. They analyze negative cardiovascular trial results for Novartis's HORIZON and Novo Nordisk's ZEUS, noting that biomarker reductions did not translate to clinical success. The hosts also cover Allist's AST-1001 receiving Phase 1 clearance, a proposed investment in Lifetech Scientific, and de-extinction tool companies. They emphasize that trial permissions and biomarker changes require patient outcome validation before assuming efficacy.

Key takeaways

  1. 1
    Akeso's ivonescimab has entered China's priority review pathway for first-line advanced biliary tract cancer, a regulatory step distinct from marketing approval.

    Ning · 1:00

  2. 2
    THE ANTIBODY COMBINES TWO JOBS BLOCKING PD1 AN IMMUNE BREAK THAT CANCERS CAN EXPLOIT AND VEGF A SIGNAL INVOLVED IN BLOOD VESSEL GROWTH IN HARMONY GI1 IT WAS COMPARED WITH DERVALUMAB ANOTHER IMMUNE TREATMENT , WITH CHEMOTHERAPY IN BOTH GROUPS NOT CHEMOTHERAPY ALONE

    Ning · 1:45

  3. 3
    At the planned interim analysis, median survival was 14.9 months with the Ivonescumab combination against 12.1 with the Dervalumab combination. NETS, That's a comparison between groups, not extra months promised to every patient.

    Basil Lui · 2:10

  4. 4
    Serious medical events during treatment occurred in about 43% of patients in each group.

    Ning · 2:27

  5. 5
    Xilox Tonbridge's effective economic interest in Lifetech Scientific is approximately 10%, calculated as 60% ownership of a joint vehicle that holds a 16.7% stake.

    Basil Lui · 8:01

Episode sections

  1. 0:05 – 1:00

    Intro and AI-voice disclosure

    Basil Lui introduces the East-West Bio Brief for November 8, 2026, outlining topics including Akeso's cancer drug review, cardiovascular trial details, and biotech beyond biotech. Ning confirms the use of AI-cloned voices and states the content is personal views, not investment advice.

  2. 1:00 – 3:06

    Akeso: review versus approval

    Ning reports that Akeso's ivonescimab has entered China's priority review pathway for first-line advanced biliary tract cancer. Basil Lui clarifies that this is a regulatory step distinct from marketing approval, referencing prior survival data from the Harmony GI1 trial.

  3. 3:06 – 4:41

    China: trial steps and infrastructure

    Ning discusses Allist's AST-1001 entering clinical testing in China following US clearance, and a subsidiary's application for a pandemic influenza mRNA vaccine. Basil Lui notes infrastructure developments at a Shanghai cell therapy company and Wuxi.

  4. 4:41 – 7:29

    HORIZON, ZEUS and Eastern context

    Basil Lui details negative cardiovascular trial results for Novartis's HORIZON and Novo Nordisk's ZEUS presented at the AHA meeting. Ning contrasts these with Asian approaches, including Hygieia's Chylo-11 and Chugai's tocilizumab, emphasizing that biomarker changes do not equal clinical success.

  5. 7:29 – 9:07

    Beyond: vascular-device investment

    Ning describes a proposed investment by Xilox Tonbridge and GL Capital into Lifetech Scientific. Basil Lui explains the ownership structure, noting Xilox's effective 10% economic interest via a joint vehicle subscribing for HK$1.482 billion in new shares.

  6. 9:07 – 11:28

    Beyond: egg-bioreactor tools

    Basil Lui reports on Colossal Biosciences suing a former executive. Ning and Basil Lui connect de-extinction tools to egg-based protein production services offered by Donga Sciences, Avinogen, and All Bio, distinguishing between platform capabilities and approved commercial products.

  7. 11:28 – 12:21

    What to watch and Monday sign-off

    Basil Lui concludes that priority review and trial permissions are process steps, not evidence of efficacy, and that biomarker results require patient outcome validation. The hosts direct listeners to Spotify, Apple Podcasts, and the LinkedIn newsletter for the weekly edition.

Claims worth verifying

Akeso's ivonescimab entered China's priority review pathway for first-line advanced biliary tract cancer on November 5.

Ning ·1:00

How to verify: Check Akeso's official company press release dated November 5, 2026, or the National Medical Products Administration (NMPA) of China's drug review announcements. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

The Harmony GI1 trial enrolled 682 patients in China.

Basil Lui ·2:03

How to verify: Review the Partner Summit October release or Akeso's clinical trial data presentations detailing the Harmony GI1 study enrollment numbers. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

In the Harmony GI1 interim analysis, median survival was 14.9 months with ivonescimab combination versus 12.1 months with durvalumab combination.

Basil Lui ·2:10

How to verify: Access the interim analysis data from the Harmony GI1 trial published in Akeso's investor presentations or clinical trial registries (e.g., ClinicalTrials.gov). For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Serious medical events during treatment occurred in about 43% of patients in each group in the Harmony GI1 trial.

Ning ·2:27

How to verify: Review the safety data section of the Harmony GI1 interim analysis report from Akeso or the Partner Summit October release. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Allist's AST-1001 can enter clinical testing in China following US trial clearance in October.

Ning ·3:06

How to verify: Check Allist's official announcement dated November 6, 2026, and US FDA records for AST-1001 investigational new drug (IND) clearance. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Primary source

Novartis reported HORIZON missed its primary endpoint in September.

Basil Lui ·4:50

How to verify: Review Novartis's official press release or investor presentation from September 2026 regarding the HORIZON trial results. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Novo Nordisk reported ZEUS missed its primary endpoint in July.

Basil Lui ·4:54

How to verify: Review Novo Nordisk's official press release or investor presentation from July 2026 regarding the ZEUS trial results. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

The ZEUS trial enrolled 6,376 adults with cardiovascular disease, kidney disease, and raised inflammation.

Basil Lui ·5:43

How to verify: Check the Novo Nordisk ZEUS trial press release or the American Heart Association (AHA) meeting abstracts for the ZEUS study design and enrollment numbers. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

In the ZEUS trial, serious infections occurred in 20% of the ziltivekimab group versus 18% with placebo.

Basil Lui ·5:53

How to verify: Review the safety results from the ZEUS trial presented at the AHA meeting or in Novo Nordisk's official disclosure. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Xilox Tonbridge and GL Capital proposed investing HK$1.482 billion in new shares of Lifetech Scientific to acquire a 16.7% stake via a vehicle.

Basil Lui ·8:09

How to verify: Check Lifetech Scientific's official stock exchange announcement regarding the proposed investment and joint vehicle subscription. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify Akeso's ivonescimab priority review status and timeline via China's NMPA announcements or Akeso investor relations filings.
  • Review the full Harmony GI1 trial data and statistical methodology to understand the comparison against durvalumab plus chemotherapy.
  • Analyze the Novartis HORIZON and Novo Nordisk ZEUS trial primary endpoint results and safety data from conference presentations or press releases.
  • Check Lifetech Scientific's latest filings for details on the Xilox Tonbridge and GL Capital investment structure and effective ownership percentages.
  • Confirm Allist's AST-1001 Phase 1 clinical trial status and regulatory clearances in China and the US via clinical trial registries or company announcements.
  • Investigate the specific biomarker reductions vs clinical outcomes in IL-6 inhibitor trials to assess the validity of the biomarker-to-outcome assumption.
  • Review Colossal Biosciences litigation details and Donga Sciences/Avinogen/All Bio service offerings to distinguish platform capabilities from commercial products.
Full transcriptexpand
0:05
Basil Lui: BIO TECH ANNOUNCEMENT CHANGE WHAT HAPPENS NEXT? AND WHEN DOES A BETTER BLOOD TEST NUMBER FAIL TO HELP PATIENTS?
0:14
Basil Lui: We start in China with Arceso's cancer drug review, then pair new cardiovascular trial details with earlier Asian research. beyond biotech, vascular devices, and the connection BETWEEN DE-EXTINCTION TOOLS AND PROTEINS MADE IN EGGS
0:31
Basil Lui: I'm Basil Lui, investing globally from Singapore with an Asia angle. This is the East-West BioBrief, Biotech and Beyond, for Sunday, November 8th. This edition includes our Sunday morning news check.
0:45
Ning: And I'm Ning. As always, these are our own voices, AI-cloned, so we can bring you this brief. Personal views, not investment advice. We will distinguish this weekend's new detail from earlier results and background.
1:00
Ning: Start with AKESO, in Chinese, Kangfang Shenwu. Its November 5th company release says Ivonecimab, a cancer antibody plus chemotherapy, has entered China's priority review pathway for FIRST first-line LINE ADVANCED BILIARY TRACK CANCER. THOSE CANCERS AFFECT THE BIAL DUCKS AND GALL BLADDER.
1:21
Ning: FIRST LINE MEANS THE INITIAL TREATMENT FOR ADVANCED DISEASE.
1:25
Basil Lui: On November 2nd, we covered the survival result behind this application. This follow-up is a regulatory step, not another trial readout. Priority review moves the application forward, but isn't marketing APPROVAL FOR THIS CANCER THE DISTINCTION MATTERS WHEN TRACKING WHAT PATIENTS CAN ACTUALLY RECEIVE
1:45
Ning: THE ANTIBODY COMBINES TWO JOBS BLOCKING PD1 AN IMMUNE BREAK THAT CANCERS CAN EXPLOIT AND VEGF A SIGNAL INVOLVED IN BLOOD VESSEL GROWTH IN HARMONY GI1 IT WAS COMPARED WITH DERVALUMAB ANOTHER IMMUNE TREATMENT , WITH CHEMOTHERAPY IN BOTH GROUPS NOT CHEMOTHERAPY ALONE
2:03
Basil Lui: According to Partner Summit's October release, the trial enrolled 682 patients in China.
2:10
Basil Lui: At the planned interim analysis, median survival was 14.9 months with the Ivonescumab combination against 12.1 with the Dervalumab combination. NETS, That's a comparison between groups, not extra months promised to every patient.
2:27
Ning: Serious medical events during treatment occurred in about 43% of patients in each group. They weren't necessarily caused by the drugs. The company described safety as manageable, but that doesn't mean harmless. These are company-reported findings from an interim analysis in China, not a completed global evidence package.
2:46
Basil Lui: The next evidence to watch is the regulatory decision and further trial follow-up.
2:51
Basil Lui: Summit has separately announced a US study with the ECOG-ACRIN research group. That needs its own evidence. A positive Chinese trial doesn't finish development elsewhere or establish approval outside China.
3:06
Ning: ALIST in Chinese ALIS announced on November 6th that AST-1001 can enter clinical testing in China, following U.S. trial clearance in October. It's an antibody carrying a cell-killing payload, targeting EGFR and CMAT in advanced solid cancers. Does permission on both sides tell us whether it works?
3:27
Basil Lui: No, it allows the company to investigate it. This is phase one, not evidence of clinical benefit. As with the different CSPC antibody drug conjugate, we covered on November 7th, the next meaningful evidence comes from patients receiving the treatment. These
3:47
Basil Lui: aren't head-to-head programs.
3:57
Ning: SUBSIDIARIES APPLICATION TO TEST THE PANDEMIC INFLUENZA MRNA VACCINE HAS BEEN ACCEPTED. CLINICAL WORK MAY PROCEED IF NO NEGATIVE OR QUESTIONING OPINION ARRIVES WITHIN 60 DAYS. ACCEPTANCE ISN'T TRIAL CLEARANCE. AND THERE ARE NO CLINICAL RESULTS HERE.
4:21
Basil Lui: A cell therapy company established in Shanghai's Linggang area and construction started on a nearly 200 million yuan building upgrade at Wuxi. That's infrastructure advancing, not proof that newly completed capacity is already supplying patients.
4:41
Basil Lui: Now to the full cardiovascular trial details presented at the American N.HART Heart Association meeting on Saturday. The negative top lines were already known.
4:50
Basil Lui: NOVATIS Novartis. REPORTED HORIZONS MISSED IN SEPTEMBER,
4:54
Basil Lui: AND NOVO-NORDISK REPORTED ZEUSES IN JULY. THIS WEEKEND ADDS DETAIL, NOT TWO NEWLY DISCOVERED FAILURES.
5:09
Ning: NOVONAUTIS ZILTIFECIMAB is an experimental
5:33
Ning: MAJOR CARDIOVASCULAR EVENTS
5:36
Basil Lui: NOVONAUTIS ZILTIFECIMAB IS AN EXPERIMENTAL ANTIBODY BLOCKING IL-6, AN INFLAMMATORY SIGNAL.
5:43
Basil Lui: ZOOS ENROLLED 6,376 ADULTS WITH CARDIOVASCULAR DISEASE, KIDNEY DISEASE, AND RAISED INFLAMMATION.
5:53
Basil Lui: A BLOOD MARKER OF INFLAMMATION FELL SUBSTANTIALLY, BUT HEART ATTACKS, TECS, STROKES, AND CARDIOVASCULAR DEATHS WEREN'T SIGNIFICANTLY REDUCED. SERIOUS INFECTIONS OCCURRED IN 20% VERSUS 18% WITH PLACEBOL.
6:07
Basil Lui: SO DOES ASIA HAVE COMPARABLE APPROACHES OR DO THOSE RESULTS SETTLE THE QUESTION FOR EVERYONE WORKING ON THESE TARGETS?
6:15
Ning: THEY DON'T SETTLE EVERY APPROACH. ACCORDING TO ITS DEVELOPER, CHINA DEVELOPED CHYLO-11 FROM Hygieia HYGIA, PART OF SINO-BIOPHARMACEUTICAL, , USES A DIFFERENT KIND OF GENETIC medicine to reduce LPA production. Its small first-in-human study showed a durable fall in that marker. Those results predate this
6:35
Ning: weekend. They don't demonstrate fewer heart attacks.
6:38
Basil Lui: On inflammation, tocilizumab was created by Japan's Chugai with Osaka University. It blocks the receptor receiving the IL-6 signal rather than the signal itself.
6:52
Basil Lui: IN AN OLDER NORWEGIAN HEART ATTACK TRIAL,
6:54
Basil Lui: IT IMPROVED AN MRI MEASURE OF HEART MUSCLES SAVED. THAT SMALL STUDY DIDN'T ESTABLISH FEWER DEATHS OR RECURRENT CARDIOVASCULAR EVENTS.
7:09
Ning: Not Equivalent Clinical Successes Different medicines, patients, and study designs can give different answers. The next decisive evidence is whether a treatment improves patient outcomes with acceptable risks, not simply how far it moves a blood marker.
7:33
Ning: Xilox Tonbridge in Chinese, Guichuang Tongqiao, and GL Capital proposed investing in Lifetech Scientific in Chinese, Xian Jian Keji. Their devices address blood vessel disease and conditions affecting the heart structure. If the joint vehicle gets
7:53
Ning: 16.7% of Lifetech, does Zilog's Xilox Tonbridge itself own that whole stake?
8:01
Basil Lui: No. Its effective economic interest would be about 10% because it would own 60% of the vehicle.
8:09
Basil Lui: The vehicle would subscribe for roughly HK$1.482 billion of new shares. 16.7% and 10% describe different layers of the arrangement,
8:21
Basil Lui: not conflicting valuations.
8:24
Ning: According to the company release, the proposed fit is between Xylox StormBridge's peripheral and brain vessel devices, and Lifetech's products for the aorta, the body's main artery,
8:37
Ning: and conditions affecting the heart's structure. That's a broader portfolio on paper, not evidence of better NETA clinical results from the proposed combination.
8:48
Basil Lui: Nor is this a completed merger. The investment is conditional and the release says a merger may be pursued. Completion of the investment is the immediate milestone. Any later merger would need to be assessed separately rather than counted as something that has already happened.
9:07
Basil Lui: Our other beyond story starts with Colossal, The the company pursuing de-extinction.
9:13
Basil Lui: New York Post reported on Nov. 6 that it had sued a former executive over alleged misuse of confidential research. Those are allegations, not findings of wrongdoing.
9:26
Basil Lui: We aren't deciding the dispute here. But how does this connect to proteins made in eggs?
9:33
Ning: THROUGH TOOLS FOR WORKING WITH THE CELLS THAT GIVE RISE TO A BIRD'S EGGS OR SPERM, DONGA SCIENCES MAY REPORT DESCRIBES EDITING THOSE REPRODUCTIVE PRECURSOR CELLS SO CHANGES CAN PASS INTO FUTURE BIRDS. THE REPORT CONNECTS THE TOOLKIT WITH BOTH BIRD RESTORATION RESEARCH AND EGG-BASED PROTEIN
9:52
Ning: PRODUCTION. THAT'S BACKGROUND, NOT A NEW SUNDAY BREAKTHROUGH.
9:56
Basil Lui: THE PRACTICAL DISTINCTION IS WHAT THE RESEARCHERS WANT THE BIRD TO DO. One project may aim to restore traits trade associated with an extinct species. Another introduces genetic instructions so the bird produces a useful protein in its eggs. Shared techniques don't make the goals, products or businesses equivalent.
10:16
Ning: In Korea, Avinogen describes making recombinant proteins in gene-edited eggs. X, Recombinant means Proteins produced using engineered genetic INSTRUCTIONS. ITS COMPANY SITE ALSO OFFERS CUSTOMIZED EDITED CELL LINES AND POULTRY MODELS. THAT'S ITS
10:36
Ning: PLATFORM DESCRIPTION, NOT EVIDENCE THAT AN APPROVED MEDICINE IS BEING MANUFACTURED AT COMMERCIAL SCALE.
10:45
Basil Lui: All Bio gives a concrete service example.
10:49
Basil Lui: Its website describes introducing a gene into those reproductive precursor cells, breeding the edited chickens, and collecting the target protein from the egg white.
10:59
Basil Lui: It lists immune signaling proteins and antibodies among the examples. According to the company, it's a contract protein production service.
11:09
Ning: So the useful comparison isn't whether these companies are all bringing back extinct animals. It's what each PLATFORM ACTUALLY PRODUCES AND WHAT EVIDENCE SUPPORTS THE INTENDED USE. A PROTEIN PRODUCTION SERVICE ISN'T AUTOMATICALLY AN APPROVED MEDICINE. A SHARED CELLULAR TOOLKIT ISN'T AUTOMATICALLY THE SAME COMMERCIAL OPPORTUNITY.
11:33
Basil Lui: IT CHANGES THE NEXT DECISION PRIORITY REVIEW CHANGES A REGULATORY PATHWAY TRIAL PERMISSION OPENS AN EXPERIMENT
11:41
Basil Lui: AND A POWERFUL BIOMARKER RESULT STILL HAS TO EARN ITS PLACE THROUGH PATIENT OUTCOMES ACROSS EAST AND WEST, THE NEXT EVIDENCE MATTERS MORE THAN THE BIGGEST NUMBER
11:52
Basil Lui: IF THIS BRIEF IS USEFUL, FOLLOW THE EASTWEST BIOBRIEF ON SPOTIFY AI, OR APPLE PODCASTS
11:59
Ning: And subscribe to the East West Biobrief newsletter on LinkedIn. It goes out every Monday with our weekly roundup. That's today's brief. The key sources are in the show notes. See you on Monday for the weekly edition.
This page was produced automatically: the audio was transcribed with whisperx-large-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-GGUF:UD-Q4_K_XL. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from The East-West Bio Brief

The East-West Bio Brief

Daily, Sun 15 Nov: Beijing adds 107 drugs, Europe says yes. Who wins?

Episode discussion: China adds 107 drugs to insurance list; Europe backs lung cancer treatments; FDA decision pending for ivonescimab

Speakers’ claims: Speakers report that China's National Healthcare Security Administration added 107 new drugs to its 2026 National Reimbursement Drug List, including a record 51 Class 1 innovative drugs. JW Therapeutics' CAR-T therapy and Novo Nordisk's insulin-semaglutide combination were highlighted as notable additions. In Europe, the EMA's CHMP backed Hansoh's aumolertinib and Innovent's sintilimab for lung cancer. Meanwhile, the FDA's decision on Akeso's ivonescimab remained pending as of the episode's recording. The speakers also discussed US regulatory restrictions on genetic data exports and their impact on clinical trials.

China HealthcarePharmaceuticalsFDA Approval
12 min0 assets10 claims to verify
The East-West Bio Brief

Daily, Sat 14 Nov: FDA decision day for ivonescimab, Akeso's lung cancer bispecific

Episode discussion: FDA decision day for Akeso's ivonescimab; BioNTech buys voucher; Intellia deadline set

Speakers’ claims: Basil Lui and AI co-host Ning discuss the November 14 FDA decision deadline for Akeso's ivonescimab, a PD1/VEGF bispecific licensed to Summit Therapeutics. They analyze the HARMONi trial results, noting progression-free survival benefits but missed statistical significance in overall survival, complicated by a trial population weighted 60% toward Asian patients. The episode contrasts Akeso's path with BioNTech's purchase of a priority review voucher and highlights Intellia's upcoming March 2027 deadline for its CRISPR therapy lonvo-z.

FDA ApprovalOncologyBiotech
11 min1 assets10 claims to verify
All insights